Cargando…

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

BACKGROUND: Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway. In preclinical studies, the pan-PI3K inhibitor buparlisib showed antitumour activity in glioma models. METHODS: This was a two-part, multicentre, phase Ib/II study in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenthal, Mark, Clement, Paul M, Campone, Mario, Gil-Gil, Miguel J, DeGroot, John, Chinot, Olivier, Idbaih, Ahmed, Gan, Hui, Raizer, Jeffrey, Wen, Patrick Yung, Pineda, Estela, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Mason, Warren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359195/ https://www.ncbi.nlm.nih.gov/pubmed/32665311 http://dx.doi.org/10.1136/esmoopen-2020-000672

Ejemplares similares

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
por: Wen, Patrick Yung, et al.
Publicado: (2020)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Lung toxicity of lomustine in the treatment of progressive gliomas
por: Seliger, Corinna, et al.
Publicado: (2022)

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
por: Bardia, Aditya, et al.
Publicado: (2019)

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2019)

A phase II study of buparlisib in relapsed or refractory thymomas
por: Abu Zaid, Mohammad I., et al.
Publicado: (2022)

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
por: Punt, C. J., et al.
Publicado: (1997)

Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
por: Ren, Xing, et al.
Publicado: (2021)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
Publicado: (2018)

Lomustine induced acute pulmonary toxicity in a pediatric medulloblastoma survivor
por: Radhakrishnan, Venkatraman, et al.
Publicado: (2017)

Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma
por: Smallwood, Katherine, et al.
Publicado: (2020)

Lomustine’s nanoemulsion as nose-to-brain drug delivery system for CNS tumor treatment
por: Alaayedi, Maryam H., et al.
Publicado: (2023)

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
por: Reardon, D A, et al.
Publicado: (2009)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies
por: Luo, Qian, et al.
Publicado: (2019)

P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB
por: Alves, Raquel, et al.
Publicado: (2023)

Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas
por: Kim, Young-Joo, et al.
Publicado: (2015)

Carnosic acid impedes cell growth and enhances anticancer effects of carmustine and lomustine in melanoma
por: Lin, Kun-I, et al.
Publicado: (2018)

Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells
por: Chakkath, Thushara, et al.
Publicado: (2015)

Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review
por: Irfan, Nabia, et al.
Publicado: (2020)

Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro
por: Kapteijn, Maaike Y., et al.
Publicado: (2023)

Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro
por: Fuchs, Daniel, et al.
Publicado: (2023)

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
por: Fishman, Hila, et al.
Publicado: (2023)

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016)

Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
por: Bohnacker, Thomas, et al.
Publicado: (2017)

Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial
por: Martínez-García, María, et al.
Publicado: (2022)

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)
por: Lam, Ching, et al.
Publicado: (2016)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Plasma lipid profiling of different types of hepatic fibrosis induced by carbon tetrachloride and lomustine in rats
por: Ishikawa, Masaki, et al.
Publicado: (2016)

Pulse‐Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs
por: Burton, J.H., et al.
Publicado: (2015)

Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic
por: Laprais, Aurore, et al.
Publicado: (2017)

ET-02 EFFICACY OF THE SALVAGE THERAPY VIA LOMUSTINE AND NIMUSTINE FOR RECURRENT GLIOBLASTOMA WITH TEMOZOLOMIDE RESISTANCE
por: Yamamuro, Shun, et al.
Publicado: (2019)

Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance
por: Yamamuro, Shun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f05ttfqtc785fak2trd22eostv